Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 226 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2015', provides an overview of the Wet (Neovascular / Exudative) Macular Degeneration's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Wet (Neovascular / Exudative) Macular Degeneration
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Wet (Neovascular / Exudative) Macular Degeneration and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Wet (Neovascular / Exudative) Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Wet (Neovascular / Exudative) Macular Degeneration pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Wet (Neovascular / Exudative) Macular Degeneration Overview 9
Therapeutics Development 10
Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview 10
Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Comparative Analysis 11
Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies 12
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies 20
Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development 24
Alcon, Inc. 24
Allergan, Inc. 25
AlphaMab Co., Ltd 26
Amakem NV 27
Avalanche Biotechnologies, Inc. 28
Bayer AG 29
BIOCAD 30
Boehringer Ingelheim GmbH 31
Charlesson LLC. 32
Circadian Technologies Limited 33
Clearside BioMedical, Inc. 34
EyeCyte, Inc. 35
F. Hoffmann-La Roche Ltd. 36
Genzyme Corporation 37
GlaxoSmithKline plc 38
iCo Therapeutics Inc. 39
Icon Bioscience, Inc. 40
Iconic Therapeutics, Inc. 41
Intas Pharmaceuticals Ltd. 42
Kala Pharmaceuticals, Inc. 43
Lpath, Inc. 44
Mesoblast Limited 45
Neurotech Pharmaceuticals, Inc. 46
Novartis AG 47
Ohr Pharmaceutical Inc. 48
Ophthotech Corp. 49
Oxford BioMedica plc 50
PanOptica, Inc. 51
Pfenex Inc. 52
Pfizer Inc. 53
pSivida Corp. 54
Quark Pharmaceuticals, Inc. 55
Regeneron Pharmaceuticals, Inc. 56
ReGenX Biosciences, LLC 57
Resolvyx Pharmaceuticals, Inc 58
Santen Pharmaceutical Co., Ltd. 59
Sanwa Kagaku Kenkyusho Co., Ltd. 60
Tacere Therapeutics, Inc. 61
ThromboGenics NV 62
TRACON Pharmaceuticals, Inc. 63
TWi Pharmaceuticals, Inc. 64
DWet (Neovascular / Exudative) Macular Degeneration - Therapeutics Assessment 65
Assessment by Monotherapy Products 65
Assessment by Target 66
Assessment by Mechanism of Action 69
Assessment by Route of Administration 72
Assessment by Molecule Type 74
Drug Profiles 76
abicipar pegol - Drug Profile 76
AC-301 - Drug Profile 78
aflibercept (recombinant) - Drug Profile 79
AGN-151200 - Drug Profile 82
ALG-1001 - Drug Profile 83
AMA-0428 - Drug Profile 85
ARC-1905 - Drug Profile 86
AVA-101 - Drug Profile 87
AVA-201 - Drug Profile 89
bertilimumab - Drug Profile 90
bevacizumab biosimilar - Drug Profile 92
BI-144807 - Drug Profile 93
BI-30089 - Drug Profile 94
C16Y Peptide - Drug Profile 95
CLT-005 - Drug Profile 96
conbercept - Drug Profile 97
DE-120 - Drug Profile 99
doxorubicin pegylated nanoparticle - Drug Profile 100
EC-200 - Drug Profile 101
EC-400 - Drug Profile 102
ENV-705 - Drug Profile 104
fluocinolone acetonide - Drug Profile 105
GB-101 - Drug Profile 107
Gene Therapy for Wet Age-Related Macular Degeneration - Drug Profile 108
GZ-402663 - Drug Profile 109
hI-con1 - Drug Profile 110
HMR-59 - Drug Profile 111
LFG-316 - Drug Profile 112
Lpathomab - Drug Profile 114
LT-1009 - Drug Profile 115
MPC-MICRO-IO - Drug Profile 119
NM-9405 - Drug Profile 120
NT-503 - Drug Profile 121
NT-506 - Drug Profile 122
ocriplasmin (recombinant) - Drug Profile 123
OPT-302 - Drug Profile 126
PAN-90806 - Drug Profile 127
pazopanib hydrochloride - Drug Profile 128
pegpleranib sodium - Drug Profile 133
PF-05206388 - Drug Profile 135
PF-655 - Drug Profile 136
ranibizumab biosimilar - Drug Profile 138
ranibizumab biosimilar - Drug Profile 139
ranibizumab biosimilar - Drug Profile 140
ranibizumab biosimilar - Drug Profile 141
REGN-21763 - Drug Profile 142
regorafenib - Drug Profile 143
RetinoStat - Drug Profile 146
RG-7716 - Drug Profile 147
RTH-258 - Drug Profile 148
RX-20001 - Drug Profile 150
SK-1011 - Drug Profile 151
Small Molecule to Inhibit Receptor Tyrosine Kinase for Wet Age-Related Macular Degeneration - Drug Profile 152
Small Molecules for Age Related Macular Degeneration - Drug Profile 153
Small Molecules to Inhibit VEGF and PDGF for Wet AMD - Drug Profile 154
Small Molecules to Inhibit VEGF for Wet AMD - Drug Profile 156
squalamine lactate - Drug Profile 158
TRC-105 - Drug Profile 161
triamcinolone acetonide - Drug Profile 163
TT-211 - Drug Profile 164
TT-231 - Drug Profile 165
X-82 - Drug Profile 166
XV-615 - Drug Profile 167
Wet (Neovascular / Exudative) Macular Degeneration - Recent Pipeline Updates 168
Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects 209
Wet (Neovascular / Exudative) Macular Degeneration - Discontinued Products 211
Wet (Neovascular / Exudative) Macular Degeneration - Product Development Milestones 212
Featured News & Press Releases 212
Appendix 221
Methodology 221
Coverage 221
Secondary Research 221
Primary Research 221
Expert Panel Validation 221
Contact Us 222
Disclaimer 222

List of Tables
Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, H1 2015 14
Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration - Comparative Analysis, H1 2015 15
Number of Products under Development by Companies, H1 2015 17
Number of Products under Development by Companies, H1 2015 (Contd..1) 18
Number of Products under Development by Companies, H1 2015 (Contd..2) 19
Number of Products under Development by Companies, H1 2015 (Contd..3) 20
Comparative Analysis by Late Stage Development, H1 2015 21
Comparative Analysis by Clinical Stage Development, H1 2015 22
Comparative Analysis by Early Stage Development, H1 2015 23
Products under Development by Companies, H1 2015 24
Products under Development by Companies, H1 2015 (Contd..1) 25
Products under Development by Companies, H1 2015 (Contd..2) 26
Products under Development by Companies, H1 2015 (Contd..3) 27
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Alcon, Inc., H1 2015 28
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Allergan, Inc., H1 2015 29
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by AlphaMab Co., Ltd, H1 2015 30
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Amakem NV, H1 2015 31
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Avalanche Biotechnologies, Inc., H1 2015 32
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Bayer AG, H1 2015 33
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by BIOCAD, H1 2015 34
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Boehringer Ingelheim GmbH, H1 2015 35
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Charlesson LLC., H1 2015 36
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Circadian Technologies Limited, H1 2015 37
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Clearside BioMedical, Inc., H1 2015 38
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by EyeCyte, Inc., H1 2015 39
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 40
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Genzyme Corporation, H1 2015 41
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by GlaxoSmithKline plc, H1 2015 42
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by iCo Therapeutics Inc., H1 2015 43
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Icon Bioscience, Inc., H1 2015 44
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Iconic Therapeutics, Inc., H1 2015 45
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Intas Pharmaceuticals Ltd., H1 2015 46
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Kala Pharmaceuticals, Inc., H1 2015 47
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Lpath, Inc., H1 2015 48
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Mesoblast Limited, H1 2015 49
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Neurotech Pharmaceuticals, Inc., H1 2015 50
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Novartis AG, H1 2015 51
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ohr Pharmaceutical Inc., H1 2015 52
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ophthotech Corp., H1 2015 53
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Oxford BioMedica plc, H1 2015 54
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by PanOptica, Inc., H1 2015 55
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Pfenex Inc., H1 2015 56
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Pfizer Inc., H1 2015 57
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by pSivida Corp., H1 2015 58
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Quark Pharmaceuticals, Inc., H1 2015 59
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 60
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by ReGenX Biosciences, LLC, H1 2015 61
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Resolvyx Pharmaceuticals, Inc, H1 2015 62
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2015 63
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H1 2015 64
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Tacere Therapeutics, Inc., H1 2015 65
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by ThromboGenics NV, H1 2015 66
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by TRACON Pharmaceuticals, Inc., H1 2015 67
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by TWi Pharmaceuticals, Inc., H1 2015 68
Assessment by Monotherapy Products, H1 2015 69
Number of Products by Stage and Target, H1 2015 71
Number of Products by Stage and Mechanism of Action, H1 2015 74
Number of Products by Stage and Route of Administration, H1 2015 77
Number of Products by Stage and Molecule Type, H1 2015 79
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics - Recent Pipeline Updates, H1 2015 172
Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects, H1 2015 213
Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects (Contd..1), H1 2015 214
Wet (Neovascular / Exudative) Macular Degeneration - Discontinued Products, H1 2015 215